How to Order Lumvoa

Lumvoa™
veligrotug-vvze

Product Overview[1]

Product Name	Lumvoa
How Supplied	500 mg/10 mL single-dose vial
NDC	10-Digit: 85166-001-01
	11-Digit*: 85166-**0**001-01

Lumvoa is available through an authorized specialty pharmacy and distributor network.

Authorized Specialty Pharmacy

Accredo®
1-800-803-2523
www.accredo.com/raretherapies/prescribers

Authorized Distributor Network

BioCareSD
1-800-304-3064
www.biocare-us.com

CuraScript Specialty Distribution
1-877-599-7748
www.curascript.com

Cardinal Health SPD
1-855-855-0708
www.cardinalhealth.com

Cardinal Health PR 120, Inc. Specialty Pharmaceutical Division
1-787-625-4200
www.cardinalhealth.pr

Metro Medical Supply, Inc.
1-800-768-2002
www.metromedical.com

ASD Healthcare
1-800-746-6273
www.asdhealthcare.com

Besse Medical Supply
1-800-543-2111
www.besse.com

Oncology Supply
1-800-633-7555
www.oncologysupply.com

McKesson Specialty Health
1-855-477-9800
www.mckesson.com

McKesson Plasma & Biologics
1-877-625-2566
www.mckesson.com

*FDA standard NDC has been "zero-filled" to ensure creation of an 11-digit code that meets HIPAA standards. The zero-fill location is indicated in **bold**.

FDA, US Food and Drug Administration; HIPAA, Health Insurance Portability and Accountability Act; NDC, National Drug Code.

Please see Important Safety Information on page 2 and Full Prescribing Information.

Indication and Important Safety Information

Indication: Lumvoa is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

Important Safety Information

Infusion Reactions: Lumvoa may cause infusion reactions. Infusion reactions have been reported in approximately 9% of patients treated with Lumvoa. Signs and symptoms of infusion-related reactions include transient increases in blood pressure, fever, chills, headache, and fatigue. Infusion reactions may occur during or soon after an infusion. Reported infusion reactions are usually mild or moderate in severity and can usually be successfully managed with corticosteroids, antihistamines, and antipyretics. In patients who experience an infusion reaction, consideration should be given to standard premedication and/or administering infusions at a slower infusion rate.

Inflammatory Bowel Disease: Lumvoa may cause an exacerbation of inflammatory bowel disease (IBD). IBD has been reported in some patients receiving insulin-like growth factor-1 receptor inhibitors without a prior diagnosis of IBD. Monitor patients for signs and symptoms of IBD, including patients without a history of IBD. If IBD is suspected, discontinue use of Lumvoa.

Hyperglycemia: Hyperglycemia or increased blood glucose may occur in patients treated with Lumvoa. In clinical trials, 12% of patients, of whom one half had preexisting diabetes or impaired glucose tolerance, experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with Lumvoa. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving Lumvoa. Continued monitoring after treatment is recommended for patients who experience hyperglycemia while on Lumvoa.

Hearing Impairment Including Hearing Loss: Lumvoa may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients' hearing before, during, and after treatment with Lumvoa and consider the benefit-risk of treatment with patients.

Most Common Adverse Events: Most common adverse reactions (incidence of 5% or more) are muscle spasms, headache, hearing impairment, hyperglycemia, fatigue, diarrhea, ear discomfort, infusion-related reaction, nausea, nasopharyngitis, blood creatine phosphokinase increased, dry skin, and hypertension.

Females of Reproductive Potential: Appropriate forms of contraception should be implemented prior to initiation, during treatment, and for 6 months following the last dose of Lumvoa.

Lumvoa (500 mg) is an injection for infusion.

Please see Full Prescribing Information.

Reference: 1. Lumvoa™ (veligrotug-vvze) prescribing information. Viridian Therapeutics, Inc. 2026.

Lumvoa™
veligrotug-vvze

VIRIDIAN